We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Identifies Mechanism Underlying a Form of Sensory Nerve Damage

By LabMedica International staff writers
Posted on 27 Apr 2016
Print article
Image: Altered caudal fin morphology following paclitaxel injection into larval zebrafish at 2 dpf. (A) Morphological changes (arrows) in the fin fold 1 hour after injection with 10 µM paclitaxel (insets show higher magnification). (B) Fin damage (arrows) 3 hour after paclitaxel injection. (C) Vehicle controls with undamaged fins 4 hour postinjection. (Scale bar, 200 µm.) hpinj = hours postinjection. (Image courtesy of Lisse TS et al, 2016, PNAS.)
Image: Altered caudal fin morphology following paclitaxel injection into larval zebrafish at 2 dpf. (A) Morphological changes (arrows) in the fin fold 1 hour after injection with 10 µM paclitaxel (insets show higher magnification). (B) Fin damage (arrows) 3 hour after paclitaxel injection. (C) Vehicle controls with undamaged fins 4 hour postinjection. (Scale bar, 200 µm.) hpinj = hours postinjection. (Image courtesy of Lisse TS et al, 2016, PNAS.)
Researchers have discovered a mechanism that underlies induction of peripheral neuropathy (PN) by the chemotherapeutic agent paclitaxel, raising the prospects for developing treatments for this and possibly also for certain other forms of PN. The work may also lead to companion diagnostics to identify patients who would benefit from these new therapies.

The study was led by Sandra Rieger, PhD, of Mount Desert Island Biological Laboratory (Bar Harbor, ME, USA). "Our goal is to develop treatments that activate the repair and regeneration of damaged tissues," said Kevin Strange, PhD, president, MDI Biological Laboratory, "Sandra Rieger's research has advanced that mission.”

Peripheral nerve damage is a common condition (e.g. ~8 million people are affected in the US) that causes increasing pain and numbness and/or tingling in the hands and/or feet. Lack of understanding of underlying mechanisms has held back development of treatments. Drugs exist for the treatment of symptoms (e.g. pain relievers), but not for the condition itself, which can be caused by chemotherapy, diabetes, traumatic injury, heredity, and other conditions.

"The general thinking is that no single drug can be effective for the treatment of all PNs, which stem from multiple causes," said Dr. Rieger, "But our research indicates that there may potentially be a common underlying mechanism for some neuropathies affecting the sensory nervous system that could be manipulated with drugs targeting a single enzyme."

Dr.Rieger and other scientists at the institution's Davis Center for Regenerative Medicine study tissue repair, regeneration, and aging in a diverse range of organisms that have robust mechanisms to repair and regenerate lost and damaged tissues. In the new study, zebrafish were exposed to paclitaxel, used to treat ovarian, breast, lung, pancreatic, and other cancers. Paclitaxel-induced PN affects the majority of treated patients; however, those who are most severely affected (~30%) have to terminate chemotherapy early or reduce the dose, which may hinder cancer survival.

The researchers developed a larval zebrafish model of PN because the embryos develop rapidly and larval fish are translucent, ideal for studying progression of nerve degeneration in live animals. The results showed that paclitaxel induced degeneration of sensory nerve endings by damaging the epidermis (outer layer of skin), which is innervated by free sensory nerve endings that establish direct contact with skin cells. The degeneration was determined to be caused by perturbations in the epidermis due to an increase in the enzyme matrix-metalloproteinase 13 (MMP-13), which degrades the collagen between the cells. Increased MMP-13 activity may be triggered by oxidative stress, a hallmark of diabetic PN.

The zebrafish were treated with pharmacological agents that reduce MMP-13 activity, with the result that skin defects were improved and chemotherapy-induced nerve damage was reversed. Additional research will focus on effect of MMP-13 on PN in mammalian models. Studies are also underway in collaboration with Mayo Clinic (Rochester, MN, USA) to test the clinical relevance of these findings in humans. PN treatment using MMP-13- targeting compounds is now the subject of a provisional patent by MDI Biological Laboratory.

MMP-13 over-activation has also been linked to other disease conditions, including tendon injury, intestinal inflammatory, and cancer, suggesting that drugs developed to treat PN may yield other health benefits as well.

The study, by Lisse TS et al, was published March 28, 2016, in the journal Proceedings of the National Academy of Sciences.

Related Links:
Mount Desert Island Biological Laboratory

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.